Testosterone Therapy Does Not Raise Prostate Cancer Recurrence Risk
After radical prostatectomy, men who received testosterone therapy for hypogonadism had a lower rate of biochemical recurrence than nonhypogonadal men.
After radical prostatectomy, men who received testosterone therapy for hypogonadism had a lower rate of biochemical recurrence than nonhypogonadal men.
BMI and waist circumference declined in hypogonadal men treated with parenteral testosterone undecanoate.
Researchers studied 850 testosterone-deficient men who received 1,000 mg parenteral testosterone undecanoate six weeks after baseline and then every 12 weeks for up to five years.
In fact, men on testosterone replacement therapy (TRT) had a lower PCa rate than men not on TRT.
Many men even experience an improvement in lower urinary tract symptoms.
Hypogonadal men aged 65 years and older experience significant benefit from TRT over 12 months.
California researchers have found that low testosterone levels occur five times more often among men taking long-acting opioids.
Researchers reviewed clinical trial and postmarketing data.
Testosterone deficiency is common in many patients with CKD, but the treatment of this deficiency and associated side effects have not always received much attention.
Researchers predict about 1.3 million new cases of cardiovascular disease related to low testosterone over a 20-year period.